Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 28.04 B
The data is delayed by 15 minutes.
ALXN is in the long-term up 2052% in 24 years.
Description: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||224.02 M||EPS||3.07||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||17.14%||Sales Growth - Q/Q||0.14%||P/E||37.13|
|P/E To EPS Growth||P/S||12.36||P/BV||7.97||Price/Cash Per Share||14.56|
|Price/Free Cash Flow||55.69||ROA||13.34%||ROE||16.74%||ROI||15.36%|
|Current Ratio||4.92||Quick Ratio||4.61||Long Term Debt/Equity||0.05||Debt Ratio||0.17|
|Gross Margin||90.72%||Operating Margin||33.65%||Net Profit Margin||25.97%||Dividend Payout Ratio|
|Cash From Financing Activities||5.07 M||Cash From Investing Activities||-48.42 M||Cash From Operating Activities||23.03 M||Gross Profit||584.2 M|
|Net Profit||170.22 M||Operating Profit||181.08 M||Total Assets||13.17 B||Total Current Assets||2.53 B|
|Total Current Liabilities||769.17 M||Total Debt||3.5 B||Total Liabilities||4.61 B||Total Revenue||636.21 M|
|High 52 week||139.01||Low 52 week||93.94||Last close||111.7||Last change||-0.03%|
|RSI||80.37||Average true range||4.01||Beta||1.14||Volume||2.37 M|
|Simple moving average 20 days||7.77%||Simple moving average 50 days||-1.17%||Simple moving average 200 days||-6.46%|
|Performance Week||1.58%||Performance Month||2.07%||Performance Quart||-8.06%||Performance Half||-16.82%|
|Performance Year||-8.04%||Performance Year-to-date||14.73%||Volatility daily||2.7%||Volatility weekly||6.05%|
|Volatility monthly||12.39%||Volatility yearly||42.94%||Relative Volume||244.27%||Average Volume||1.74 M|
|New High||New Low|
2019-03-19 09:48:54 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
2019-03-12 10:29:25 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
2019-03-11 21:28:07 | Dicerna Pharmaceuticals Inc DRNA Q4 2018 Earnings Conference Call Transcript
2019-03-08 09:05:00 | Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® Eculizumab in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve
2019-03-06 09:30:02 | Why Is Alexion ALXN Up 9.7% Since Last Earnings Report?
2019-03-06 08:35:00 | Analysis: Positioning to Benefit within Bristol-Myers Squibb, AAR, Central Garden & Pet, Alexion Pharmaceuticals, Tribune Media, and Civitas Solutions — Research Highlights Growth, Revenue, and Consolidated Results
2019-03-06 04:43:38 | Mass. life science leaders say outgoing FDA head was an 'advocate for modernization'
2019-03-05 16:30:00 | Alexion to Present at the Cowen 39th Annual Health Care Conference
2019-03-01 13:46:04 | Final trades: Six Flags, Alexion Pharma, Alphabet, American Express & the financials
2019-02-28 14:44:21 | These 10 New Drugs Expected In 2019 Are On The Blockbuster Track
2019-02-28 08:30:00 | Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day
2019-02-26 12:15:58 | America's 'inefficient' health care system is driving our fiscal instability: Powell
2019-02-25 15:25:04 | 5 Clinical Stage Biotech Stocks to Buy
2019-02-21 16:30:00 | Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2019-02-21 09:00:00 | Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4
2019-02-20 16:45:56 | IBD 50 Stocks To Watch: Top Biotech Alexion Moves Into Buy Range
2019-02-14 13:00:06 | Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
2019-02-12 15:18:08 | Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
2019-02-12 09:00:00 | Alexion Announces Creation of New Roles on Executive Leadership Team
2019-02-11 08:39:01 | Is Alexion ALXN a Great Growth Stock?
2019-02-08 08:05:26 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
2019-02-07 07:55:00 | Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences — Renewed Outlook, Key Drivers of Growth
2019-02-04 16:13:42 | Biotech Reports Solid Fourth Quarter, But Slips On Mixed Guidance
2019-02-04 16:11:33 | Stocks rise amid next batch of corporate earnings
2019-02-04 15:29:37 | Edited Transcript of ALXN earnings conference call or presentation 4-Feb-19 1:00pm GMT
2019-02-04 14:46:38 | Alexion Pharmaceuticals ALXN Q4 2018 Earnings Conference Call Transcript
2019-02-04 12:45:05 | Alexion's ALXN Earnings Beat Estimates in Q4, Shares Up
2019-02-04 11:57:05 | Stocks making the biggest moves midday: Papa John's, Sysco, Clorox & more
2019-02-04 10:38:03 | Economic & Earnings Data Deluge
2019-02-04 10:26:03 | Q4 Earnings Soldier on Gamely: GOOGL, CLX & More
2019-02-04 08:54:18 | Stocks Open Mixed, Dow Jones Drags Ahead Of Alphabet Earnings
2019-02-04 08:39:00 | Here's Why Alexion Pharmaceuticals Gained 26.3% in January
2019-02-04 08:30:01 | Alexion ALXN Tops Q4 Earnings and Revenues Beat Estimates
2019-02-04 07:48:04 | Stocks making the biggest moves premarket: Papa John's, Spotify, Clorox, Yelp & more
2019-02-04 06:52:34 | Alexion: 4Q Earnings Snapshot
2019-02-04 06:33:00 | Evolus Rises Midday as Botox Drama Unfolds
2019-02-04 06:30:00 | Alexion Reports Fourth Quarter and Full Year 2018 Results
2019-02-01 14:06:00 | Why Amgen Should Buy Alexion Pharmaceuticals
2019-02-01 06:30:00 | Alexion to Highlight Rare Disease Portfolio at Investor Day
2019-01-31 19:26:12 | Alexion ALXN to Report Q4 Earnings: What's in the Cards?
2019-01-31 06:30:00 | Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals
2019-01-29 11:10:04 | Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
2019-01-28 10:01:57 | Stock Market Tumbles On Caterpillar Earnings Miss, Nvidia Warning
2019-01-25 07:55:00 | Analysis: Positioning to Benefit within Cigna, Alexion Pharmaceuticals, Synchrony Financial, Global Medical REIT, Investors Real Estate Trust, and CPI Card Group — Research Highlights Growth, Revenue, and Consolidated Results